Brings Decades of Pharmaceutical Research and Management Experience, Including Serving in Senior Roles at Pfizer and Eli Lilly Company HIGH POINT, N.C. --(BUSINESS WIRE)--Dec. 2, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that Larry Altstiel has joined the company as Chief Medical
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 24, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease (AD) and diabetes, announced that Stephen Holcombe , President
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 13, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease (AD) and diabetes, today announced that Stephen Holcombe ,
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 12, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease (AD) and diabetes, today reported financial results for the
HIGH POINT, N.C. --(BUSINESS WIRE)--Oct. 22, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Dr.
HIGH POINT, N.C. --(BUSINESS WIRE)--Sep. 28, 2015-- First paragraph, second sentence of release dated September 23, 2015 , should read: The presentation will take place at 2:00 pm EDT on Tuesday, September 29 at the Sofitel Hotel in New York City (instead of: The presentation will take place at
HIGH POINT, N.C. --(BUSINESS WIRE)--Sep. 23, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Stephen Holcombe , President
HIGH POINT, N.C. --(BUSINESS WIRE)--Jul. 29, 2015-- vTv Therapeutics Inc. (the “Company”) (Nasdaq:VTVT) announced today the pricing of its initial public offering of 7,812,500 shares of its Class A common stock at a price to the public of $15.00 per share.
vTv Therapeutics Inc. (the “Company”) today announced the launch of its initial public offering in the United States of 7,812,500 shares of its Class A common stock. The initial public offering price is currently expected to be between $15.00 and $17.00 per share of Class A common stock. The
High Point, North Carolina (June 29, 2015) vTv Therapeutics LLC (vTv), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced the appointment of Rudy C.